Aug. 24, 2026 — Tempus AI, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes ...
Hypertension
This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.
-
-
July 9, 2026 — A new artificial intelligence (AI) clinical tool developed by researchers at the University of Maryland Institute for Health Computing (UM-IHC) and the University of Maryland School of ...
-
May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone synthase inhibitor (ASI) for treating hypertension in combination with other ...
-
April 2, 2026 — Omron Healthcare Co. has launched a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection ...
Aug. 24, 2026 — Tempus AI, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...
August 24, 2026
Aug. 18, 2026 — Murj, a cardiac device management software and services company, has released of its Murj Remote Patient ...
August 19, 2026
July 16, 2025 — Insmed Inc. recently announced positive 12-Month data from the ongoing open-label extension (OLE) study ...
July 20, 2026
July 9, 2026 — A new artificial intelligence (AI) clinical tool developed by researchers at the University of Maryland ...
July 09, 2026
June 9, 2026.— Pentixapharm Holding AG has announced that the U.S. Food and Drug Administration (FDA) has cleared its ...
June 09, 2026
May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone ...
May 18, 2026
April 2, 2026 — Omron Healthcare Co. has launched a randomized controlled trial in collaboration with the University of ...
April 03, 2026
March 28, 2026-- At ACC.26, Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial examining the ...
April 02, 2026
March 28, 2026 — Medtronic has announced the EMBRACE trial, led by Dr. Roxana Mehran, Professor of Medicine and Director ...
March 31, 2026
Jan. 16, 2026 — MemorialCare Heart & Vascular Institute has launched the FDA-approved Symplicity Renal Denervation (RDN) ...
January 19, 2026
Oct. 30, 2025 — Recor Medical and its parent company, Otsuka Medical Devices presented the results from two clinical ...
November 03, 2025
Feature | Renal Denervation | Kyle Hardner
Hypertension remains the leading modifiable driver of cardiovascular disease and premature death.1 Even with multiple ...
October 02, 2025
Sept. 04, 2025 — CorVista Health has published a new case series in the Journal of the American College of Cardiology ...
September 09, 2025
Sept. 5, 2025 — Idorsia Ltd has announced a first-of-its-kind initiative with the Stanford Hypertension Center and Duke ...
September 08, 2025
Aug. 19, 2025 — Idorsia Ltd recently announced its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan ...
August 27, 2025